For example, retinoic acid receptor alpha (RARA) positivity, which may be present in many mutational subtypes, is correlated with sensitivity to tamibarotene [89, 90]; there are on-going clinical trials of this agent in RARA expressing AML and MDS (NCT04905407 and NCT04797780). This evidence concerns the gene RARA and acute myeloid leukemia.